SPS PGD template for the supply and/or administration of subcutaneous medroxyprogesterone acetate (SC-DMPA) injection for contraception.

Provenance

Developed by SPS and the Faculty of Sexual and Reproductive Health (FSRH), with the support of specialist stakeholders working within clinical practice, for contraception commonly supplied or administered within reproductive services.

PGD template attachment

The template PGD is attached below to download and use in conjunction with our implementation advice.

More reproductive health PGD templates

All PGD templates

Templates

National PGD templates are developed with experts for clinical specialties. They reduce duplication and variation, and improve consistency of care.

Update history

  1. Updated PGD template published - statement added regarding a suggested link between the prolonged use of medroxyprogesterone acetate and a small increased risk of intracranial meningioma in line with FSRH statement. Added exclusion of meningioma as per SPC.
  1. Version 2.1 published - minor changes to align with updated FSRH guidance
  1. Title, URL and summary amended.
  2. Expiring template removed.
  1. Version 2.0 PGD template added
  1. Published

Print this page